^
EZH2 rs201135441C>T
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
J Genet - 2 weeks
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
ER mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
exemestane
Resistant: B - Late Trials
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: C2 – Inclusion Criteria
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
FTO expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
BIN3 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
ER Y537S
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: C3 – Early Trials
CDK6 overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant: C3 – Early Trials
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
NOS2 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
HPGD underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
CCNE1 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CDK2 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CCND1 amplification
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CCNE1-H
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
ER-L
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
enobosarm
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + CB-228
Sensitive: C3 – Early Trials
76-gene signature
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
RET overexpression
Estrogen Receptor Positive Breast Cancer
vandetanib
Sensitive: C3 – Early Trials
RET overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: C3 – Early Trials
FOXD1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + GDC-0032
Sensitive: C3 – Early Trials
WSB2 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
letrozole
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
venetoclax
Sensitive: C3 – Early Trials
CCND1 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
AGR2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
CCNB2 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
BCL2 positive
Estrogen Receptor Positive Breast Cancer
venetoclax
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
AKT1 E17K
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive: C3 – Early Trials
NCOR2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
35-gene signature
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Resistant: C3 – Early Trials
35-gene signature
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Resistant: C3 – Early Trials
KDR V297I
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
SLBP expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
RBPMS expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ixazomib
Sensitive: C3 – Early Trials
SOX9 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
RUNX3 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ponatinib
Sensitive: C3 – Early Trials
IL6R overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
MLN8237
Sensitive: C3 – Early Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab + paclitaxel
Sensitive: C3 – Early Trials
AR positive
Estrogen Receptor Positive Breast Cancer
enobosarm
Sensitive: C3 – Early Trials
ER overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
sunitinib
Sensitive: C3 – Early Trials
NODAL overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
SALL4 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
TRIM3 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
AGR2-H
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
SOX2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Sensitive: C3 – Early Trials
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Sensitive: C3 – Early Trials
BRCA2 overexpression
Estrogen Receptor Positive Breast Cancer
olaparib
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + PF-05212384
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
apalutamide
Sensitive: D – Preclinical
ER Y537S
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: D – Preclinical
FGFR1 amplification
Estrogen Receptor Positive Breast Cancer
ponatinib
Sensitive: D – Preclinical
AURKA overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: D – Preclinical
ER D538G
Estrogen Receptor Positive Breast Cancer
AZD9833
Sensitive: D – Preclinical
AR overexpression
Estrogen Receptor Positive Breast Cancer
RAD140
Sensitive: D – Preclinical
ER Y537S
Estrogen Receptor Positive Breast Cancer
OP-1250
Sensitive: D – Preclinical
CCNE1 overexpression
Estrogen Receptor Positive Breast Cancer
RGT-419B
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
RGT-419B
Sensitive: D – Preclinical
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
palbociclib + VRx-510
Sensitive: D – Preclinical
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
ribociclib + VRx-510
Sensitive: D – Preclinical
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
ribociclib + VRx-510
Sensitive: D – Preclinical
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
palbociclib + VRx-510
Sensitive: D – Preclinical
PAK4 deletion
Estrogen Receptor Positive Breast Cancer
ribociclib + VRx-510
Sensitive: D – Preclinical
PAK4 deletion
Estrogen Receptor Positive Breast Cancer
palbociclib + VRx-510
Sensitive: D – Preclinical
HER-2 positive
Estrogen Receptor Positive Breast Cancer
ZEN-3694
Sensitive: D – Preclinical
HER-2 negative
Estrogen Receptor Positive Breast Cancer
ZEN-3694
Sensitive: D – Preclinical
MYC amplification
Estrogen Receptor Positive Breast Cancer
YPN005
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
MLN4924
Sensitive: D – Preclinical
PLK1 overexpression
Estrogen Receptor Positive Breast Cancer
anastrozole
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + CGM097
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
CGM097
Sensitive: D – Preclinical
FGFR2 mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant: D – Preclinical